Evidence map›Paper›PMID 34197617›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2022

Reporting Treatment Fidelity in Behavioral Tobacco Treatment Clinical Trials: Scoping Review and Measurement Recommendations.

Ramzi G Salloum, Alana M Rojewski, Megan E Piper, Janice A Blalock, Belinda Borrelli, Lindsay M Boyce, Jennifer A Minnix, Omara Dogar, Rachel L Tomko, Douglas E Jorenby and 2 more

Abstract readScoping Review
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Recommendations for Standardization of Tobacco Use Treatment Data.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ramzi G SalloumDepartment of Health Outcomes and Biomedical Informatics, University of Florida, College of Medicine, Gainesville, FL, USA.ORCID 0000-0002-8139-2418
Alana M RojewskiDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0003-1531-9287
Megan E PiperCenter for Tobacco Research and Intervention, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0002-9876-5460
Janice A BlalockDepartment of Behavioral Science, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Belinda BorrelliCenter for Behavioral Science Research, Boston University, Henry M. Goldman School of Dental Medicine, Boston, MA, USA.ORCID 0000-0002-0859-796X
Lindsay M BoyceDepartment of Psychiatry and Behavioral Science, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jennifer A MinnixDepartment of Behavioral Science, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Omara DogarDepartment of Health Sciences, University of York, York, United Kingdom.ORCID 0000-0002-7122-8403
Rachel L TomkoDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0002-6961-4399
Douglas E JorenbyCenter for Tobacco Research and Intervention, University of Wisconsin-Madison, Madison, WI, USA.
Chris KotsenDepartment of Psychiatry and Behavioral Science, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jamie S OstroffDepartment of Psychiatry and Behavioral Science, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tobacco Treatment in the Context of Lung Cancer Screening - Administrative SupplementK07CA214839 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ROJEWSKI, ALANA · 2017 to 2021
$911k
NCI NIH HHS K07 CA214839NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

introductionAdoption of rigorous standards for reporting treatment fidelity is essential for advancing discovery, validation, and implementation of behavioral treatments. Whereas the NIH Behavior Change Consortium (BCC) developed an assessment tool to assess the quality of reporting and monitoring of treatment fidelity across health behavior change interventions, it has not yet been applied specifically to treatment fidelity in behavioral tobacco treatment trials. AIMS AND

methodsWe conducted a scoping review of peer-reviewed, clinical trials of behavioral adult tobacco treatment interventions published in English between 2006 and 2018. Using the BCC treatment fidelity checklist, articles were coded for the presence or absence of various treatment fidelity strategies within each of 5 domains: Design, Training, Delivery, Receipt, and Enactment. Eligible articles (N = 755) were coded by two independent coders.

resultsThe proportion of reporting strategies varied within the fidelity domains, ranging from 5.2% to 96.3% in Design, 1.9% to 24.9% in Training, 2.6% to 32.3% in Delivery, 5.2% to 44.3% in Receipt, and 6.7% to 43.2% in Enactment. The mean proportion of adherence to treatment fidelity strategies within each domain was: Design (68%), Training (14%), Delivery (15%), Receipt (16%), and Enactment (25%). Only 11 studies achieved ≥80% reporting across >1 fidelity domain. There was no evidence for improvement in fidelity reporting across the 13-year time frame from the initial BCC publication to the present.

conclusionsThese findings illustrate the lack of consistency in fidelity reporting in tobacco treatment trials and underscore the challenges faced in evaluating rigor and reproducibility, as well as interpretation and dissemination of findings. Recommendations are made for improving fidelity reporting in tobacco treatment trials. IMPLICATIONS: The SRNT Treatment Research Network sponsored a scoping review to summarize the current state of reporting treatment fidelity and make recommendations for best practices in reporting fidelity in tobacco treatment trials. The review identified a lack of consistency in fidelity reporting, illustrating the challenges faced in evaluating rigor, and reproducibility, as well as interpretation and dissemination of findings.

Indexed as

Behavior TherapyAdultHealth BehaviorHumansReproducibility of ResultsTobacco ProductsTobacco Use

Identifiers

PMID34197617
PMCPMC9013002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.